HomeCompareSECO vs ABBV

SECO vs ABBV: Dividend Comparison 2026

SECO yields 493.95% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SECO wins by $55889.49M in total portfolio value
10 years
SECO
SECO
● Live price
493.95%
Share price
$0.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55889.59M
Annual income
$39,971,107,299.38
Full SECO calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SECO vs ABBV

📍 SECO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSECOABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SECO + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SECO pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SECO
Annual income on $10K today (after 15% tax)
$41,985.68/yr
After 10yr DRIP, annual income (after tax)
$33,975,441,204.47/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SECO beats the other by $33,975,420,148.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SECO + ABBV for your $10,000?

SECO: 50%ABBV: 50%
100% ABBV50/50100% SECO
Portfolio after 10yr
$27944.85M
Annual income
$19,985,566,035.57/yr
Blended yield
71.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SECO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.4
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SECO buys
0
ABBV buys
0
No recent congressional trades found for SECO or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSECOABBV
Forward yield493.95%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$55889.59M$102.3K
Annual income after 10y$39,971,107,299.38$24,771.77
Total dividends collected$54501.93M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SECO vs ABBV ($10,000, DRIP)

YearSECO PortfolioSECO Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$60,095$49,394.91$11,550$430.00+$48.5KSECO
2$341,721$277,418.96$13,472$627.96+$328.2KSECO
3$1,839,940$1,474,299.52$15,906$926.08+$1.82MSECO
4$9,387,553$7,418,817.01$19,071$1,382.55+$9.37MSECO
5$45,419,933$35,375,250.59$23,302$2,095.81+$45.40MSECO
6$208,558,746$159,959,418.35$29,150$3,237.93+$208.53MSECO
7$909,606,358$686,448,499.81$37,536$5,121.41+$909.57MSECO
8$3,771,288,805$2,798,010,001.77$50,079$8,338.38+$3771.24MSECO
9$14,877,088,953$10,841,809,931.10$69,753$14,065.80+$14877.02MSECO
10$55,889,592,479$39,971,107,299.38$102,337$24,771.77+$55889.49MSECO

SECO vs ABBV: Complete Analysis 2026

SECOStock

Secoo Holding Limited, through its subsidiaries, operates an integrated online and offline shopping platform in the People's Republic of China, Hong Kong, and internationally. It provides upscale brand products and services, including handbags, watches, clothing, footwear, jewelry and accessories, cosmetics and skincare, home accessories, sportswear, home goods, fine food and beverage products, arts, 3C electronic devices, and Chinese original products, as well as lifestyle services through its website, mobile applications, and offline experience centers. The company also offers its website as a marketplace to third party merchants to facilitate their sales of upscale products and services. Secoo Holding Limited was incorporated in 2011 and is headquartered in Beijing, China.

Full SECO Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SECO vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SECO vs SCHDSECO vs JEPISECO vs OSECO vs KOSECO vs MAINSECO vs JNJSECO vs MRKSECO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.